-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明，無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Silverback Therapeutics (NASDAQ:SBTX) Shares Up 3.4%
Silverback Therapeutics (NASDAQ:SBTX) Shares Up 3.4%
Silverback Therapeutics, Inc. (NASDAQ:SBTX – Get Rating) shares shot up 3.4% during mid-day trading on Wednesday . The company traded as high as $5.48 and last traded at $5.44. 115,799 shares traded hands during trading, a decline of 70% from the average session volume of 383,529 shares. The stock had previously closed at $5.26.
Analyst Upgrades and Downgrades
Separately, Stifel Nicolaus dropped their price objective on Silverback Therapeutics from $6.00 to $5.00 in a report on Friday, May 13th. Five equities research analysts have rated the stock with a hold rating, According to data from MarketBeat.com, the company has an average rating of "Hold" and a consensus price target of $33.00.
Get Silverback Therapeutics alerts:Silverback Therapeutics Trading Up 3.4 %
The firm has a fifty day simple moving average of $4.78 and a two-hundred day simple moving average of $4.02. The stock has a market cap of $192.98 million, a PE ratio of -2.12 and a beta of 0.65.
Institutional Trading of Silverback Therapeutics
Several institutional investors and hedge funds have recently modified their holdings of SBTX. Acadian Asset Management LLC purchased a new position in shares of Silverback Therapeutics during the 4th quarter valued at about $522,000. Bailard Inc. bought a new position in Silverback Therapeutics during the 4th quarter worth approximately $213,000. Ensign Peak Advisors Inc bought a new position in Silverback Therapeutics during the 4th quarter worth approximately $2,730,000. Schroder Investment Management Group grew its position in Silverback Therapeutics by 3.2% during the 4th quarter. Schroder Investment Management Group now owns 161,173 shares of the company's stock worth $1,073,000 after acquiring an additional 5,037 shares during the last quarter. Finally, GSA Capital Partners LLP bought a new position in Silverback Therapeutics during the 4th quarter worth approximately $77,000. Hedge funds and other institutional investors own 74.89% of the company's stock.About Silverback Therapeutics
(Get Rating)
Silverback Therapeutics, Inc, a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver.
See Also
- Get a free copy of the StockNews.com research report on Silverback Therapeutics (SBTX)
- Is World Wresting Entertainment Getting Ready to Be Sold?
- 3 Materials Stocks That May Earn a Place on Your Watchlist
- Crowdstrike Stock Retraces, As Earnings Sober Expectations
- Will The Institutions Buy The Dip In Ambarella Stock?
- PVH Corporation Is On Track For Capital Returns
Receive News & Ratings for Silverback Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silverback Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
Silverback Therapeutics, Inc. (NASDAQ:SBTX – Get Rating) shares shot up 3.4% during mid-day trading on Wednesday . The company traded as high as $5.48 and last traded at $5.44. 115,799 shares traded hands during trading, a decline of 70% from the average session volume of 383,529 shares. The stock had previously closed at $5.26.
銀背治療公司(納斯達克代碼：SBTX-GET評級)的股價在週三午盤交易中飆升3.4%。該公司股價一度高達5.48美元，最新報5.44美元。當日共有115,799股股票成交，較385,529股的平均成交量下降了70%。該股此前收盤價為5.26美元。
Analyst Upgrades and Downgrades
分析師升級和下調評級
Separately, Stifel Nicolaus dropped their price objective on Silverback Therapeutics from $6.00 to $5.00 in a report on Friday, May 13th. Five equities research analysts have rated the stock with a hold rating, According to data from MarketBeat.com, the company has an average rating of "Hold" and a consensus price target of $33.00.
另外，Stifel Nicolaus在5月13日星期五的一份報告中將Silverback治療公司的目標價格從6.00美元下調至5.00美元。根據MarketBeat.com的數據，五位股票研究分析師對該股的評級為持有，該公司的平均評級為持有，共識目標價為33.00美元。
Silverback Therapeutics Trading Up 3.4 %
銀背治療公司股價上漲3.4%
The firm has a fifty day simple moving average of $4.78 and a two-hundred day simple moving average of $4.02. The stock has a market cap of $192.98 million, a PE ratio of -2.12 and a beta of 0.65.
該公司的50日簡單移動均線切入位在4.78美元，200日簡單移動均線切入位在4.02美元。該股市值為1.9298億美元，市盈率為-2.12，貝塔係數為0.65。
Institutional Trading of Silverback Therapeutics
銀背療法的制度性交易
About Silverback Therapeutics
關於銀背治療公司
(Get Rating)
(獲取評級)
Silverback Therapeutics, Inc, a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver.
Silverback Treateutics，Inc.是一家生物製藥公司，開發組織靶向療法，用於治療慢性病毒感染、癌症和其他嚴重疾病。該公司提供SBT8230來治療慢性乙肝病毒感染，方法是通過靶向肝臟的TLR8激活來激發抗病毒免疫反應。
See Also
另請參閲
- Get a free copy of the StockNews.com research report on Silverback Therapeutics (SBTX)
- Is World Wresting Entertainment Getting Ready to Be Sold?
- 3 Materials Stocks That May Earn a Place on Your Watchlist
- Crowdstrike Stock Retraces, As Earnings Sober Expectations
- Will The Institutions Buy The Dip In Ambarella Stock?
- PVH Corporation Is On Track For Capital Returns
- 免費獲取StockNews.com關於銀背療法(SBTX)的研究報告
- 世界摔跤娛樂公司準備被出售了嗎？
- 3種可能在你的觀察名單上獲得一席之地的材料類股
- CrowdStrike股價回落，盈利超出預期
- 這些機構會在安巴雷拉入股抄底嗎？
- PVH公司有望實現資本回報
Receive News & Ratings for Silverback Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silverback Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受《銀背治療日報》的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Silverback Treeutics和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧